COMP <GO>
MMED vs MRK // EV/EBITDA & P/E VALUATION
MiniMed Group Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: MMED 2
— MRK 12
■ METRIC PARITY
LAST: $18.28 (-5.04%) • MKT CAP: $5.42B
valuation
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MMED VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MMED | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.20% | 74.80% | -20.60 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.90% | 20.70% | -24.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.75% | 3.42% | -11.17 | MRK | /fcf-yield <GO> |
| Operating Margin | -6.10% | 34.30% | -40.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | -10.70% | 28.10% | -38.80 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 14.30% | 1.30% | +13.00 | MMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.82 | 5.19 | -0.37 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.60% | +0.50 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.8 | 56.9 | -13.04 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.92 | +0.13 | MMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 18.4x | +5.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.42B | $361.02B | -$355.61B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MMED REV | MRK REV | MMED GROSS % | MRK GROSS % | MMED FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.10B | $65.01B | 54.2% | 74.8% | -$420.0M | $12.36B |
| FY 2024 | $2.71B | $64.17B | 56.3% | 76.3% | -$53.0M | $18.10B |
| FY 2023 | $2.47B | $60.12B | 44.0% | 44.0% | -$70.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MMED // BETA 1.05
MRK // BETA 0.92